In a gut-wrenching video posted by Savannah Guthrie, the “Today Show” host said her family received a message and they “will pay” ransom money to have their 84-year-old mother returned.

“We received your message and we understand,” Savannah Guthrie said in a video posted Saturday night. “We beg you now to return our mother to us, so we can celebrate with her. This is the only way we will have peace.”

“This is very valuable to us,” she added. “And we will pay.”

In the somber video, Savannah Guthrie is holding hands with her two siblings, Annie and Camron.

Nancy Guthrie was forcefully taken from her home in Catalina Hills outside of Tucson, Arizona, in the early morning hours of February 1, according to authorities.

BREAKING

In a new video, Savannah Guthrie, joined by her sister and brother, speaks directly to the person or persons who abducted their mother, Nancy, and says she will pay the ransom to have her returned. pic.twitter.com/DJMHYaLWdV

— Yashar Ali 🐘 (@yashar) February 7, 2026

President Donald Trump on Friday night told the press that the feds would likely soon be able to provide “definitive” answers or a “solution” concerning the capture of Nancy.

“I’ll give you a little statement,” Trump said. “I think we’re doing very well, very well, meaning, we have some clues I think that are very strong, and I think we could have some answers coming up fairly soon.”

“I’m not talking about a search, I’m talking about a solution,” the president continued. “We have some things I think that will maybe come out reasonably soon from [Department of Justice] or FBI, or whoever that could be — that could be definitive.”

Trump said on February 4 that he spoke to Savannah Guthrie and let her know that he was “directing ALL Federal Law Enforcement to be at the family’s, and Local Law Enforcement’s, complete disposal, IMMEDIATELY.”

“We are deploying all resources to get her mother home safely,” he added. “The prayers of our Nation are with her and her family. GOD BLESS AND PROTECT NANCY!”

On Feb. 5, police confirmed during a press conference that blood found on the front porch of Nancy Guthrie’s home was indeed hers.

Pima County Sheriff Chris Nanos updated the public on the investigation at a recent press conference. While law enforcement has neither identified a suspect nor person of interest, Nanos said that more samples of DNA in addition to the blood on the porch had been sent in for analysis.

The sheriff also said that his office, with help from other law enforcement, including the FBI, have been investigating dozens of tips in the search for Guthrie.

“Right now, we still believe Nancy is still out there,” said Nanos.

Law enforcement on Thursday released an estimated timetable of Guthrie’s disappearance and revealed that a home camera, one that attached to Guthrie’s front doorbell, was disconnected and removed. Investigators have still not located the missing camera.

Multiple ransom notes with deadlines have been sent following Guthrie’s disappearance, demanding millions of dollars in Bitcoin.

On Friday, Guthrie’s vehicle was towed from her home, according to NBC News. Authorities have not released information detailing why the car was towed.

Tim Pearce contributed to this report.

Online telehealth company Hims & Hers on Saturday reversed course on its launch of a $49 compounded version of Novo Nordisk’s Wegovy weight-loss pill after the U.S. Food and Drug Administration said it would take action against it.

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” the telehealth firm said.

The FDA said on Friday that it plans to restrict GLP-1 ingredients used in compounded drugs that companies such as Hims and online pharmacies have marketed, citing concerns over quality, safety and potential violations of federal law.

The Department of Health and Human Services said on Friday it would refer the company to the Department of Justice but did not make clear whether it could quickly halt the sale of the Hims’ product, the cheapest GLP-1 therapy on the U.S. market.

Reuters reported on Thursday that Hims would begin offering copies of Novo Nordisk’s new Wegovy pill at an introductory price of $49 per month, about $100 less than the brand name.

The news caused a selloff in shares of Novo and rival Eli Lilly, whose own pill is expected to launch in April. The shares recovered some of the losses on Friday after FDA Commissioner Dr. Marty Makary tweeted his concern after the market’s close on Thursday while Hims’ shares fell.

“No one should be mass-compounding or selling knockoff GLP-1 products regardless of how they’re administered,” a Lilly spokesperson said in a statement to Reuters on Saturday after Hims & Hers said it would stop offering its GLP-1 pill.

Compounding, in which pharmacies mix ingredients for specialized medicines or to copy a drug but at different dosages, has flourished as Americans chase cheaper prices for drugs. The practice is legal under the Federal Food, Drug and Cosmetic Act in certain circumstances.

Novo on Thursday responded to Hims’ launch by threatening legal action against the company while Lilly, which has battled compounded copies of its injectable drug Zepbound, said that patients deserved better than copies with no clinical evidence.

Hims’ compounded drug is not FDA-approved and has not gone through clinical trials to prove efficacy.

Novo did not immediately respond to a Reuters request for comment on Saturday.

Hims & Hers did not respond to a Reuters query about whether it would continue selling compounded semaglutide injections on its website. The company, alongside Novo and Lilly, is spending millions during Sunday’s Super Bowl to promote its offerings.

Novo has been losing share in the weight-loss market to rival Lilly and telehealth firms like Hims. Novo and Hims had a partnership in 2025 allowing Hims to sell injectable Wegovy, but the two companies walked away with Novo saying Hims had wrongfully marketed copycats of Wegovy. Hims’ CEO Andrew Dudum accused Novo of attempting to control how clinicians at Hims make decisions.

Makary said in a statement on Friday that the agency will “use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns.”

HHS, which oversees the FDA, was not immediately available for comment.

(Reporting by Anusha Shah and Amina Niasse; Editing by Caroline Humer and Andrea Ricci)